{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-051835","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.461588+00:00","generated_at":"2026-05-28T23:59:23.690974+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"AIM ImmunoTech officers Equels and Rodino voluntarily forego 2024 cash bonuses to fund Ampligen R&D","bullets":["CEO Thomas K. Equels and Peter W. Rodino III notified the Compensation Committee they will forgo their 2024 cash bonuses.","The voluntary waiver is intended to help AIM focus financial resources on Ampligen R&D activities.","The Compensation Committee then determined that neither will receive a cash bonus for 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-051835","json":"https://secwatch.observer/filing/0001493152-24-051835.json","markdown":"https://secwatch.observer/filing/0001493152-24-051835.md","text":"https://secwatch.observer/filing/0001493152-24-051835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315224051835/0001493152-24-051835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315224051835/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:59:23.690974+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}